Age-Related Macular Degeneration Halted by Blocking Protein to Stop Blood Vessel Growth - CCR3
News CCR3 - New therapeutic approach in the early stages of wet macular degeneration
Quelle: www.seniorjournal.com/NEWS/Health/2009/20090615-Age-RelatedMacular.htm
Age-Related Macular Degeneration Halted by Blocking Protein to Stop Blood Vessel Growth
Protein CCR3 a new target for diagnosis and treatment of AMD, the most common cause of blindness in senior citizens.
June 15, 2009 - The battle to prevent millions of senior citizens from going blind from age-related macular degeneration (AMD) appears to have received an important boost from researchers that have demonstrated that blocking the activity of a specific protein - called CCR3 - can reduce the abnormal blood vessel growth that leads to macular degeneration.
Furthermore, targeting this new protein may prove to be safer and more effective than the current treatment for the disease, which is directed at a protein called vascular endothelial growth factor or "VEGF."
The study by researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky was published yesterday in the journal Nature.
Age-related macular degeneration is the most common cause of blindness in older Americans. AMD affects 30 to 50 million people globally, and that number is expected to double in the next decade as the baby boomer generation ages.
The discovery - made in mouse models and cultured human cells - may also enable physicians to catch the disease in its earliest stages, before blood vessels have fully infiltrated and destroyed the central portion of the eye's retina - an area known as the macula - to cause vision loss.
The lead investigator was Jayakrishna Ambati, M.D., professor of ophthalmology and visual sciences and of physiology at the University of Kentucky. Ambati is a Doris Duke Charitable Foundation Distinguished Clinical Scientist and a Burroughs Wellcome Fund Clinical Scientist in Translational Research. His laboratory is also supported by the National Eye Institute of the NIH, Research to Prevent Blindness, and American Health Assistance Foundation.
"It would be much better to prevent the disease in the first place," said study co-author and principal investigator of the UNC study site, Mary Elizabeth Hartnett, M.D., a professor of ophthalmology in the UNC School of Medicine.
"An exciting implication of this study was that the CCR3 protein could be detected in early abnormal blood vessel growth, giving us the opportunity to prevent structural damage to the retina and preserve vision."
The disease is currently treated with drugs that block the effects of VEGF, a growth factor that promotes the growth of abnormal blood vessels. However, because this factor is also involved in the growth and health of normal blood vessels, concerns have been raised about the safety of its long-term use. To date, however, these anti-VEGF agents have been found to be safe.
Thus, the investigators sought to identify a new target for treatment that is specific to AMD. They detected the presence of the CCR3 protein in eye tissue from humans with AMD but not in that of individuals of similar age who did not have the disease.
When they blocked CCR3, either with drugs or through genetic engineering, they saw a decrease in the generation of abnormal blood vessels. Drugs targeting CCR3 were significantly more effective than those targeting VEGF, meaning this could represent a new therapy for the two-thirds of patients that do not respond to current treatment.
The researchers now may look to see if levels of the protein can be detected in the bloodstream in order to identify people who are at risk of developing the disease. They also plan to search for genetic changes in the CCR3 gene in patients with AMD to better understand its causes.
The National Eye Institute, a component of the National Institutes of Health, helped support this research.
UNC study co-authors along with Hartnett include Steven J. Budd, technician and Pete Geisen, former technician, both from the Hartnett laboratory; and John D. Wright, Jr., M.D., associate professor of ophthalmology.
Other sites include Nagoya City University, University of Cincinnati, University of Utah, Veterans Affairs of Salt Lake City, Kyushu University, Harvard Medical School, Oregon Health and Science University and University of Luebeck.